Top Markets
Coin of the day
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Kedudukan dalam Saham #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Harga Saham
$5.34
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$2.59M
Perubahan (1 hari)
-11.00%
Perubahan (1 tahun)
313.95%
Negara
US
Perdagangan Jupiter Neurosciences, Inc. (JUNS)

Kategori

Bilangan saham terbitan bagi Jupiter Neurosciences, Inc. (JUNS)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham Jupiter Neurosciences, Inc., bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Jupiter Neurosciences, Inc. (JUNS) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE